Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa.

ABSTRACT:

SUBMITTER: Wallblom K 

PROVIDER: S-EPMC12777436 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature